News  >  Breaking News  >  Suzhou Ribo Lands $39 Million B Round for siRNA Portfolio

Suzhou Ribo Lands $39 Million B Round for siRNA Portfolio

By Editing NAI
03/17/2017 6:50 p.m.

Suzhou Ribo Life Science, a company focused on small interfering RNA drugs, raised $39 million in a B round led by China's State Development and Investment Corporation. Founded in 2007, Ribo is developing siRNA drugs for hepatitis B, hyperlipidaemia and liver cancer. In 2012, Ribo formed a China JV with US-based Quark Pharma, also a siRNA company. Three years later, the CFDA approved the JV's Ischemic Optic Neuropathy siRNA drug for use in China.

Source: ChinaBio Today


No Comments

Please to leave a comment.

Related News

Schlumberger says bought stake in rig firm Borr Drilling
03/29/2017 1:31 a.m.
Shanghai, Beijing listed among top 20 global financial hubs
03/29/2017 12:53 a.m.
Alibaba Sells More Momo Inc Shares, Reducing Its Holding in Mobile Social Networking Firm to 14%
03/28/2017 10:59 p.m.
Oil rises on Libyan supply disruptions, likely OPEC output cut extension
03/28/2017 10:35 p.m.
China Surpasses Singapore as Malaysia’s Largest Property Investor
03/28/2017 9:33 p.m.

Upcoming Events More


GCFF Vancouver Conference 2017 - Discovering Alternative Investments in Innovation

Over the years, investors have seen how exciting opportunities in innovation have matured into solid investments. Advances in AI, Big Data, Clean Technology and Health Care have all led ... Event Info